Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis
- DOI
- 10.1212/nxi.0000000000000117
- Published
- 2015-08
- Container
- Neurology Neuroimmunology & Neuroinflammation
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1212/nxi.0000000000000117,
title = {Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis},
author = {Cris S. Constantinescu and Aliya Asher and Waldemar Fryze and Wojciech Kozubski and Frank Wagner and Jehan Aram and Radu Tanasescu and Roman P. Korolkiewicz and Maren Dirnberger-Hertweck and Stefan Steidl and Susan E. Libretto and Till Sprenger and Ernst W. Radue},
year = {2015},
journal = {Neurology Neuroimmunology \& Neuroinflammation},
doi = {10.1212/nxi.0000000000000117},
url = {https://doi.org/10.1212/nxi.0000000000000117}
}RIS
TY - JOUR TI - Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis AU - Cris S. Constantinescu AU - Aliya Asher AU - Waldemar Fryze AU - Wojciech Kozubski AU - Frank Wagner AU - Jehan Aram AU - Radu Tanasescu AU - Roman P. Korolkiewicz AU - Maren Dirnberger-Hertweck AU - Stefan Steidl AU - Susan E. Libretto AU - Till Sprenger AU - Ernst W. Radue PY - 2015 JO - Neurology Neuroimmunology & Neuroinflammation DO - 10.1212/nxi.0000000000000117 UR - https://doi.org/10.1212/nxi.0000000000000117 ER -
APA
Constantinescu, C. S., Asher, A., Fryze, W., Kozubski, W., Wagner, F., Aram, J., Tanasescu, R., Korolkiewicz, R. P., Dirnberger-Hertweck, M., Steidl, S., Libretto, S. E., Sprenger, T., & Radue, E. W. (2015). Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurology Neuroimmunology & Neuroinflammation. https://doi.org/10.1212/nxi.0000000000000117
Source records
- crossref · retrieved 2026-09-26T20:13:01.077Z